2022-05-19| Trials & Approvals

FDA Allows Resumption of Gilead’s Lenacapavir AIDS Trials

by GeneOnline
Share To

Gilead Sciences, a key player in the global AIDS drug development, announced that the FDA has lifted its previously issued clinical hold, allowing the company to proceed with clinical trials of lenacapavir, an investigational new drug (IND) for treating AIDS.

In December 2021, the FDA placed a clinical hold on the injectable AIDS drug lenacapavir due to safety concerns about the incompatibility of the glass material with lenacapavir, which is contained in a borosilicate glass vial. After Gilead switched to aluminosilicate glass and provided safety data related to compatibility, the FDA decided to remove the hold, allowing resumption of all clinical studies evaluating injectable lenacapavir.

Related article: Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations


Lenacapavir Offers Combination of Therapeutic and Pre-exposure Prophylaxis


Currently, there is no effective cure for AIDS, and patients who fail to take their medications regularly may develop HIV drug resistance, making the treatment even more difficult. In 2020, a team of researchers described a long-acting small molecule that targets the HIV capsid protein in an article published in Nature. This molecule, originally codenamed GS-6207, was then developed into lenacapavir, a long-acting HIV-1 capsid inhibitor for the treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP).

Lenacapavir is a multi-stage viral proliferation inhibitor, unlike most existing anti-HIV drugs that inhibit viral replication in a single stage, lenacapavir is long-acting and does not have cross resistance issues with other types of antiviral drugs.

Gilead is currently conducting multiple clinical trials of lenacapavir in a Phase 2/3 trial evaluating its antiviral activity known as CAPELLA. The drug is administered by a subcutaneous injection every 6 months in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. The primary outcome results, published in The New England Journal of Medicine in its May 12, 2022 issue, showed that the drug remained well tolerated after 26 weeks of administration and no serious adverse reactions were observed, confirming the drug’s safety profile.

Related article: FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention


Lenacapavir Could Be the First HIV-1 Treatment Option to Only Require 2 Injections Yearly


In May 2019, the FDA granted Breakthrough Therapy Designation for the development of lenacapavir for the treatment of HIV-1 infection in heavily treatment-experienced patients with multi-drug resistance in combination with other antiretroviral drugs. Given future approval, it will be the only HIV-1 treatment option that requires only two injections a year.

Another important recent progress for HIV long-acting drugs is the FDA’s first approval of CABENUVA in January 2021. It is a prescription regimen that requires only one injection monthly and is comprised of two separate injectable drugs: rilpivirine developed by Janssen Pharmaceuticals, and cabotegravir developed by ViiV Healthcare, a division of GSK.

© All rights reserved. Collaborate with us:
Related Post
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
Gilead Sciences Acquires CymaBay for $4.3 billion, Heralding a New Era in PBC Treatment
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
Scroll to Top